Version June 2024
| Drug | Mechanism | Condition | Number of cases reported |
| Ponatinib | Tyrosine kinase inhibitor | Gastrointestinal stromal tumor, chronic myeloid leukemia, acute lymphoblastic leukemia | 98 |
| Imatinib | Tyrosine kinase inhibitor | Gastrointestinal stromal tumor | 1 |
| Nilotinib | Tyrosine kinase inhibitor | Chronic myeloid leukemia | 1 |
| Sorafenib | Multikinase inhibitor | Nonseminomatous germ cell carcinoma | 1 |
| NR | PI3K/mTOR inhibitor | Anaplastic oligodendroglioma | 1 |
| Idelalisib and ofatumumab | PI3K inhibitor, CD20 inhibitor | Small lymphocytic leukemia | 1 |
| Idelalisib | PI3K inhibitor | Small lymphocytic leukemia | 1 |
| Telaprevir | Viral protease inhibitor | Hepatitis C virus | 1 |
| Sofosbuvir | Viral NS5B protein inhibitor | Hepatitis C virus | 1 |
| Imiquimod | TLR7 agonist | Actinic keratosis, superficial basal cell carcinoma | 4 |
| NPH insulin | Intermediate-acting insulin | Type 1 diabetes mellitus | 1 |
| Ramipril | ACE inhibitor | NR | 1 |
| Pembrolizumab | Programmed cell death protein 1 inhibitor | Squamous cell carcinoma | 1 |
| Nivolumab | Programmed cell death 1 receptor inhibitor | Hodgkin lymphoma | 1 |
| Bevacizumab | Vascular endothelial growth factor inhibitor | Age-related macular degeneration | 1 |
| Simvastatin | HMG-CoA reductase inhibitor | Hyperlipidemia | 1 |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
